EFdA-TP tetralithium

Cat. No.: HY-138561C

Molecular Formula: $C_{12}H_{14}FLi_4N_5O_{12}P_3$

Molecular Weight: 559.95

Target: HIV; Reverse Transcriptase

Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	EFdA-TP tetralithium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetralithium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetralithium inhibits HIV-1 RT with multiple mechanisms[1].
In Vitro	EFdA-TP (0.05-10 μM; for 15 min) tetralithium inhibits RT-catalyzed DNA synthesis as an ICT or DCT[1]. EFdA-TP tetralithium can block RT as a translocation-defective RT inhibitor that dramatically slows DNA synthesis, acting as a de facto immediate chain terminator[1]. EFdA-TP tetralithium can function as a delayed chain terminator, allowing incorporation of an additional dNTP before blocking DNA synthesis[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Eleftherios Michailidis, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289(35):24533-48.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA